Rallybio Corporation announced it has entered into a Securities Purchase Agreement with Johnson & Johnson Innovation ? JJDC, Inc., a Delaware corporation and issued 3,636,363 shares of Common Stock at a issue price of $1.815 for gross proceeds of $6,599,998.845 on April 10, 2024. The transaction included participation from Johnson & Johnson Innovation ?

JJDC, Inc. The investor has agreed not to effect any sale or other transfer of the Company?s Common Stock for 180 days following the Closing, subject to certain customary exceptions. The company raised funding pursuant to exemption provided under Regulation D. The transaction included participation from a single investor.